US Patent Issued to TVAX Biomedical I on Sept. 23 for "Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy" (California, Kansas Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,924, issued on Sept. 23, was assigned to TVAX Biomedical I LLC (Olathe, Kan.).

"Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy" was invented by Gary Wood (Olathe, Kan.) and Jochen Harald Stritzker (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy."

The patent was fi...